EY has acquired Ernst and Young Single Member Societe Anonyme for the Provision of Advisory Services of Aqurance, a leading Veeva services partner headquartered in Greece, known for delivering integrated clinical, commercial and digital transformation programmes for lifesciences companies worldwide.

With this acquisition, the EY value proposition has expanded by combining the EY extensive knowledge of regulatory requirements, business design, change management, programme management, technology integration deployment and business operations with Aqurance’s deep experience providing services for Veeva Vault and applications. As a new Veeva alliance partner and through the acquisition of Aqurance, the EY organisation aims to optimise and integrate Veeva solutions to improve efficiency and compliance in the lifesciences industry.?

With the designation of Premier Services Partner for Veeva Commercial Cloud and a Services Partner for Veeva Development Cloud, Aqurance brings significant experience and knowledge for customers who need application consulting across Veeva applications in both commercial and Research and Development (R&D). Its team is expected to enhance the EY organisation’s ability to support lifesciences clients as they move to Vault CRM and through Customer Relationship Management (CRM) innovation, regulatory transformation and overall platform integration. The acquisition strengthens the EY organisation’s Veeva Centers of Excellence, to support clients as they adopt and scale a proven unified platform that helps standardise and improve customer engagement, regulatory compliance and accelerate clinical trial execution. The combined capabilities aim to help lifesciences organisations harness Artificial Intelligence (AI) and enterprise data more effectively across their value chain.

Dan Mathews, Global Lifesciences Leader, EY, said, “This is a pivotal moment for the industry as lifesciences companies make critical decisions about platform migration, compliance and data integration. With the acquisition of Aqurance, the EY organisation can offer clients a more integrated pathway—strategy through execution—to unlock the full power of Veeva technology. Together, we will help companies move faster, stay compliant and use data and AI to help drive more informed decisions across the enterprise.”

With this acquisition, the EY organisation is better positioned to help deliver a single, integrated client migration capability, helping lifesciences organisations adapt quickly to market changes, regulatory shifts and the growing need for connected digital platforms. 

Dionissis Nikolopoulos, Founder and CEO, Aqurance, said, “When we considered our next chapter, we had many options, but the EY organisation stood out. The EY organisation brings the scale, global reach and credibility that allows our knowledge to make a far greater impact. By combining Aqurance’s deep Veeva knowledge with the EY organisation’s transformation capabilities, we can help clients achieve outcomes they cannot provide alone—from seamless migrations to enterprise-wide digital change that should truly help move the needle for the lifesciences industry.”